Global Plasma Fractionation Market is valued at USD 27.45 Billion in 2020 and expected to reach USD 42.66 Billion by 2027 with the CAGR of 6.5% over the forecast period.
Global Plasma Fractionation Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027. Growing prevalence of respiratory diseases, rising number of plasma collection centers and Increasing technological advancements are some of the major factors anticipated to drive the growth of Global Plasma Fractionation Market.
Plasma is a blood component, gotten from entire blood by plasmapheresis, and utilized for different therapeutic and clinical applications. Human plasma is a source of various proteins; nonetheless just few of these proteins are helpful for producing therapeutic plasma items. The process of division, extraction and purging of these proteins from the plasma is called as fractionation process. Blood plasma fractionation alludes to the overall cycles of isolating the different parts of blood plasma, which thusly is a segment of blood acquired through blood fractionation. Plasma-determined immunoglobulins are giving another story to medical care across a wide scope of immune system inflammatory sicknesses.
A portion of the regularly utilized plasma items are immune globin, coagulation factors, albumins just as inhibitors, for example, Alpha-1 antitrypsin (AAT) or Alpha-1 Proteinase Inhibitor (A1PI), Antithrombin III (AT-III) and C1 Esterase Inhibitor INH). Plasma fractionation measure is basically based on various standards like dissolvability of the items, and their physical and compound conditions such as pH levels, temperature, ionic qualities, and so on.
During COVID-19 pandemic, the plasma fractionation industry was also affected. The outbreak of COVID-19 pandemic has prompted decline in number of blood donations and plasma assortments, which has shown a decline impact the market growth. Also, disturbance in raw material supply was repaid by fall in demand for plasma subordinates in the beginning of cross country lockdowns, as elective surgeries were postponed and availability of therapy for other medical conditions was additionally hampered.
However, convalescent plasma (CP) treatment is required to expand the survival rate of COVID-19 patients. Thus, government offices of different nations, for example, the U.S. and India are taking initiatives to offer this treatment to patients as fast as possible, while simultaneously conducting the clinical trials to discover the security and effectiveness of the treatment. For instance, in April 2020, the European Commission suggested that bonding of COVID-19 convalescent plasma, as a promptly accessible test treatment with low risk, should be considered as a critical need and its result monitored.
Global plasma fractionation market reports cover prominent players
Global plasma fractionation market is segmented on the basis of product type, application, end-user, and region & country level. On the basis of product type, plasma fractionation market is classified as immunoglobulin, coagulation factor, concentrates, albumin, protease inhibitors and others. On the basis of application, the market is classified as neurology, immunology, homology, critical care, pulmonology, hemoto-oncology, rheumatology and others. On the basis of end-user, the plasma fractionation market is classified as hospitals & clinics, clinical research laboratories and academic institutes.
By Product Type:
The regions covered in global plasma fractionation market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of plasma fractionation market sub divided in U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Middle East and Africa
One of the major factors driving the growth of global plasma fractionation market is growing prevalence of respiratory diseases. For instance; according to the WHO, respiratory diseases are driving reasons for death and incapacity globally. Around 65 million people experience the chronic obstructive pneumonic disease (COPD) and 3 million die from it every year, making it the third driving reason for death around the world. Around 334 million individuals suffer from asthma; the most widely recognized chronic disease of youth influencing 14% of all youngsters worldwide. In addition, rising number of plasma collection centers are also supplementing the demand for plasma fractionation.
Furthermore, increasing technological advancements in this field are also fostering the market growth. For instance, in April 2020, Kedrion Biopharma teamed up with Kamada Ltd. The cooperation was expected to develop, manufacture, and circulate human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) item as a potential treatment for Covid patients.
However, the high cost & limited reimbursement of plasma products and growing use of recombinant alternatives may hamper the growth of global plasma fractionation market. In spite of that, rising technological developments for plasma proteins can offer major opportunities for the further growth of the global plasma fractionation market.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 27.45 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||6.5%|
|Market Size Expected in 2027:||USD 42.66 Billion|
|Tables, Charts & Figures:||175|
|Key Players/Companies||CSL, Grifols, Shire, Octapharma, Kedrion, LFB, Biotest, Sanquin, China Biologic Products, Bio Prodcuts Laboratory (BPO), Japan Blood Products Organization, Green Cross Corporation, and others.|
|Segments Covered||By Type, By Application, By End-User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
North America is expected to dominate the global plasma fractionation market with the potential rate due to increasing prevalence of respiratory diseases, and the increasing use of immunoglobulin in various therapeutic areas in this region. According to the National Center for Health Statistics, presently in excess of 25 million individuals in the United States have asthma and about 14.8 million adults have been determined to have COPD. COPD is the fourth driving reason for death in the United States.
The Asia Pacific is expected to emerge as the fastest-growing region for plasma fractionation market over the forecast period due to increasing number of plasma collection centers, high investment in drug discovery and developing healthcare research infrastructure in this region. For instance, according to the WHO, an increase of 7.8 million blood donations from charitable donors has been reported from 2013 to 2018. Only 55 of 171 reporting nations produce plasma-derived medicinal products (PDMP) during the fractionation of plasma together in the country. In April 2020, the Indian Council for Medical Research (ICMR) APPROVED Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST, India) to foster a convention for improving plasma treatment trials to treat seriously sick COVID-19 patients.